{"filing":{"accession_number":"0001104659-26-073430","cik":"0000812796","ticker":"SNGX","company_name":"SOLIGENIX, INC.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"sngx-20260610x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/sngx-20260610x8k.htm"},"events":[{"id":10759,"run_id":9440,"accession_number":"0001104659-26-073430","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Soligenix received a written notice from Nasdaq on June 10, 2026, indicating noncompliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification.","company_name":"SOLIGENIX, INC.","ticker":"SNGX","filing_date":"2026-06-12","submitted_at":null,"items":[{"id":7154,"accession_number":"0001104659-26-073430","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Soligenix received a written notice from Nasdaq on June 10, 2026, indicating noncompliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has been given 180 calendar days (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification. This is a classic delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:11.926547+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10760,"run_id":9440,"accession_number":"0001104659-26-073430","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The Company terminated its HyBryte™ development program following a Data Monitoring Committee recommendation of futility in the Phase 3 FLASH2 trial, with estimated wind-down costs of $70,000. This represents a material strategic decision to discontinue a clinical program affecting the Company's pipeline and strategic direction.","company_name":"SOLIGENIX, INC.","ticker":"SNGX","filing_date":"2026-06-12","submitted_at":null,"items":[{"id":7155,"accession_number":"0001104659-26-073430","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Dr. Richard C. Straube ceased serving as Consulting Chief Medical Officer effective June 11, 2026, following the Company's decision to terminate the HyBryte™ development program. While Straube had previously retired from his full-time CMO role in August 2025 and transitioned to consulting, this disclosure centers on his departure from the consulting role itself, with his responsibilities being transitioned to Dr. Christopher Pullion. The termination of a consulting CMO position in connection with a material program discontinuation is material to investors assessing the Company's medical leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:11.926547+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7156,"accession_number":"0001104659-26-073430","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company terminated its HyBryte™ development program following a Data Monitoring Committee recommendation of futility in the Phase 3 FLASH2 trial. This represents a material strategic decision to discontinue a clinical program, with estimated wind-down costs of $70,000. While the termination itself is material to investors assessing the Company's pipeline and strategic direction, it does not fit neatly into the more specific event categories (e.g., it is not a restatement, impairment charge, or M\u0026A activity), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:11.926547+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7154,"accession_number":"0001104659-26-073430","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Soligenix received a written notice from Nasdaq on June 10, 2026, indicating noncompliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has been given 180 calendar days (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification. This is a classic delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:11.926547+00:00","company_name":"SOLIGENIX, INC.","ticker":"SNGX","filing_date":"2026-06-12"},{"id":7155,"accession_number":"0001104659-26-073430","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Dr. Richard C. Straube ceased serving as Consulting Chief Medical Officer effective June 11, 2026, following the Company's decision to terminate the HyBryte™ development program. While Straube had previously retired from his full-time CMO role in August 2025 and transitioned to consulting, this disclosure centers on his departure from the consulting role itself, with his responsibilities being transitioned to Dr. Christopher Pullion. The termination of a consulting CMO position in connection with a material program discontinuation is material to investors assessing the Company's medical leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:11.926547+00:00","company_name":"SOLIGENIX, INC.","ticker":"SNGX","filing_date":"2026-06-12"},{"id":7156,"accession_number":"0001104659-26-073430","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company terminated its HyBryte™ development program following a Data Monitoring Committee recommendation of futility in the Phase 3 FLASH2 trial. This represents a material strategic decision to discontinue a clinical program, with estimated wind-down costs of $70,000. While the termination itself is material to investors assessing the Company's pipeline and strategic direction, it does not fit neatly into the more specific event categories (e.g., it is not a restatement, impairment charge, or M\u0026A activity), making \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:11.926547+00:00","company_name":"SOLIGENIX, INC.","ticker":"SNGX","filing_date":"2026-06-12"}]}